Continuing its M&A deal spree, Sanofi has agreed to acquire Kymab, a clinical-stage company developing antibody therapies for immune-mediated diseases and immuno-oncology. With the deal, which is worth up to US$1.45 B, Sanofi gains full control of KY1005, a potential first-in-class anti-OX40L monoclonal antibody in development for moderate-to-severe atopic dermatitis. Interestingly, the acquisition comes just five months after Kymab announced that KY1005 met the primary endpoints of a Phase IIa study.